GENE ONLINE|News &
Bristol Myers Squibb Acquires Cancer Cell Therapy Partner 2seventy Bio in $286M Deal
With this acquisition, BMS is doubling down on its commitment to advancing CAR T cell therapy and solidifying its position in multiple myeloma treatment. Image: BMS.
Bristol Myers Squibb (BMS) is taking full control of ABECMA—its blockbuster multiple myeloma cell therapy—by acquiring its partner, 2seventy bio, in a $286 million deal. …
Bristol Myers Squibb Acquires Cancer Cell Therapy Partner 2seventy Bio in $286M Deal Read More »
GO Prime with only $1.49 now
LATEST
NUS Researchers Use Evolutionary Biology Models to Map Singapore Shophouse Architectural Development
2026-08-11
City St George’s Launches €6 Million REMADE Project to Advance Circular Renovation in Urban Neighborhoods
2026-08-10
Digital Science Releases Two Model Context Protocol Servers for Dimensions Research Platform
2026-08-10
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
